NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study

被引：0
|
作者：
Gregorc, V. [1 ]
Ceresoli, G. L. [2 ]
Zucali, P. A. [2 ]
De Braud, F. G. [3 ]
Bajetta, E. [4 ]
Santoro, A. [2 ]
Vigano, M. G. [1 ]
Cappio, F. Caligaris [1 ]
Lambiase, A. [5 ]
Bordignon, C. [5 ]
机构：
[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[2] Ist Clin Humanitas, Dept Oncol, Milan, Italy
[3] Ist Europeo Oncol, Clin Pharmacol & New Drugs Unit, Milan, Italy
[4] IRCCS Fdn, Ist Nazl Tumori, Dept Oncol, Milan, Italy
[5] MolMed, Clin Dev, Milan, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71724-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：509 / 509
页数：1
相关论文
共 50 条
  • [41] Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
    Castagneto, B.
    Botta, M.
    Aitini, E.
    Spigno, F.
    Degiovanni, D.
    Alabiso, O.
    Serra, M.
    Muzio, A.
    Carbone, R.
    Buosi, R.
    Galbusera, V.
    Piccolini, E.
    Giaretto, L.
    Rebella, L.
    Mencoboni, M.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 370 - 373
  • [42] A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM).
    Alley, Evan W.
    Tanvetyanon, Tawee
    Jahan, Thierry Marie
    Gandhi, Leena
    Peikert, Tobias
    Stevenson, James
    Schlienger, Katia
    Liu, Weiqun
    Nair, Nitya
    Honarmand, Somayeh
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [43] Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours
    Gregorc, Vanesa
    Citterio, Giovanni
    Vitali, Giordano
    Spreafico, Anna
    Scifo, Paola
    Borri, Anna
    Donadoni, Giovanni
    Rossoni, Gilda
    Corti, Angelo
    Caligaris-Cappio, Federico
    Del Maschio, Alessandro
    Esposito, Antonio
    De Cobelli, Francesco
    Dell'Acqua, Flavio
    Troysi, Antonella
    Bruzzi, Paolo
    Lambiase, Antonio
    Bordignon, Claudio
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (01) : 198 - 206
  • [44] Phase II Study of NGR-hTNF Plus Doxorubicin in Relapsed Ovarian Cancer (OC)
    Lorusso, D.
    Scambia, G.
    Amadio, G.
    Trivellizzi, N.
    Pietragalla, A.
    De Vincenzo, R.
    Salutari, V.
    Di Stefano, M.
    Lambiase, A.
    Bordignon, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S536 - S536
  • [45] Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
    Pagano, Maria
    Ceresoli, Luca Giovanni
    Zucali, Paolo Andrea
    Pasello, Giulia
    Garassino, Marina
    Grosso, Federica
    Tiseo, Marcello
    Soto Parra, Hector
    Zanelli, Francesca
    Cappuzzo, Federico
    Grossi, Francesco
    De Marinis, Filippo
    Pedrazzoli, Paolo
    Gnoni, Roberta
    Bonelli, Candida
    Torricelli, Federica
    Ciarrocchi, Alessia
    Normanno, Nicola
    Pinto, Carmine
    CANCERS, 2020, 12 (10) : 1 - 12
  • [46] Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study
    Pagano, M.
    Gnoni, R.
    Bonelli, C.
    Zanelli, F.
    Garassino, M. C.
    Ceresoli, G. L.
    Pasello, G.
    Tiseo, M.
    Parra, H. J. Soto
    Grosso, F.
    Zucali, P. A.
    Larocca, M.
    Torricelli, F.
    Ciarrocchi, A.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
    Watanabe, Kageaki
    Okuma, Yusuke
    Kawai, Shoko
    Nagamata, Makoto
    Hosomi, Yukio
    THORACIC CANCER, 2021, 12 (11) : 1668 - 1672
  • [48] Phase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer (OC).
    Scambia, G.
    Lorusso, D.
    Amadio, G.
    Trivellizzi, N.
    Pietragalla, A.
    De Vincenzo, R.
    Salutari, V.
    Di Stefano, M.
    Mangili, G.
    Montoli, S.
    Citterio, G.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] A phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM).
    Wozniak, Antoinette J.
    Schneider, Bryan J.
    Kalemkerian, Gregory Peter
    Daly, Robert Michael
    Chen, Wei
    Ventimiglia, Jaclyn
    Nagasaka, Misako
    Zauderer, Marjorie Glass
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Single-Agent Pembrolizumab for Patients with Malignant Pleural Mesothelioma (MPM)
    Alley, Evan W.
    Schellens, Jan H. M.
    Santoro, Armando
    Beckey, Kim
    Yuan, Shuai Sammy
    Cheng, Jonathan
    Piperdi, Bilal
    Molife, L. Rhoda
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S195 - S195
12345